These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 16861252

  • 1. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [Abstract] [Full Text] [Related]

  • 2. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):93-103. PubMed ID: 16236307
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 5. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
    Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, Shitara K.
    J Biochem; 2006 Dec 30; 140(6):777-83. PubMed ID: 17038352
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 8. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I.
    J Immunother; 2008 Oct 15; 31(8):752-61. PubMed ID: 18779744
    [Abstract] [Full Text] [Related]

  • 9. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R.
    Cancer Res; 2008 May 15; 68(10):3863-72. PubMed ID: 18483271
    [Abstract] [Full Text] [Related]

  • 10. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
    Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T.
    Clin Cancer Res; 1998 Sep 15; 4(9):2237-43. PubMed ID: 9748144
    [Abstract] [Full Text] [Related]

  • 11. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
    Xie Z, Guo N, Yu M, Hu M, Shen B.
    J Immunol Methods; 2005 Jan 15; 296(1-2):95-101. PubMed ID: 15680154
    [Abstract] [Full Text] [Related]

  • 12. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K.
    Clin Cancer Res; 2005 Mar 15; 11(6):2327-36. PubMed ID: 15788684
    [Abstract] [Full Text] [Related]

  • 13. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
    Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K.
    Mol Immunol; 2007 May 01; 44(12):3122-31. PubMed ID: 17379311
    [Abstract] [Full Text] [Related]

  • 16. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
    Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K.
    J Mol Biol; 2004 Mar 05; 336(5):1239-49. PubMed ID: 15037082
    [Abstract] [Full Text] [Related]

  • 17. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M.
    Biotechnol Bioeng; 2004 Sep 05; 87(5):614-22. PubMed ID: 15352059
    [Abstract] [Full Text] [Related]

  • 18. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb 05; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 19. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 20. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M.
    J Biotechnol; 2007 Jun 30; 130(3):300-10. PubMed ID: 17559959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.